The guidance describes, among other
things, how FDA will determine whether the provisions of section
505(q) addressing the treatment of citizen petitions and petitions
for stay of agency action (collectively, petitions) apply to a
particular petition and whether a petition would delay approval of
a pending abbreviate new drug application or a 505(b)(2)
application. The guidance also describes the provisions of section
505(q) requiring that a petition include a certification and that
supplemental information or comments to a petition include a
verification.
There is a slight increase in
burden based on current submissions.
$1,125
No
No
No
No
No
Uncollected
ILa Mizrachi 301 796-7726
ila.mizrachi@fda.hhs.gov
No
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.